IDEAYA Biosciences (IDYA) said Monday it has entered into a research collaboration with ATTMOS to develop a physics-based small molecule discovery computational platform for undruggable oncology targets.
The companies will integrate expertise in structural biology, drug discovery, and computational chemistry to develop a high-throughput workflow for absolute binding free energy perturbation predictions of drug candidates.
The collaboration will use the Amber molecular dynamics suite for GPU-accelerated simulations, with IDEAYA incorporating its drug discovery data to train ABFEP-based active learning cycles for efficient small molecule screening, the company said.
Financial details weren't disclosed.
Shares of IDEAYA Biosciences were down more than 2% in recent Monday trading.
Price: 20.00, Change: -0.57, Percent Change: -2.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.